A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review

A pharmacological class known as immune checkpoint inhibitors (ICIs) has been developed as a potential treatment option for various malignancies, including HCC. In HCC, ICIs have demonstrated clinically significant advantages as monotherapy or combination therapy. ICIs that target programmed cell de...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharafi, Faezeh, Hasani, Sadegh Abaei, Alesaeidi, Samira, Kahrizi, Mohammad Saeed, Adili, Ali, Ghoreishizadeh, Shadi, Shomali, Navid, Tamjidifar, Rozita, Aslaminabad, Ramin, Akbari, Morteza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400240/
https://www.ncbi.nlm.nih.gov/pubmed/35999569
http://dx.doi.org/10.1186/s12935-022-02682-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400240/
https://www.ncbi.nlm.nih.gov/pubmed/35999569
http://dx.doi.org/10.1186/s12935-022-02682-z

Ejemplares similares